Alternative salmeterol/fluticasone dry powder inhaler for asthma and COPD

Aerivio Spiromax provides the same metered dose of salmeterol/fluticasone propionate as Seretide 500 Accuhaler, and is indicated for use in adults with asthma and COPD.

Patients should be trained how to use Aerivio Spiromax and advised to inhale forcefully to ensure optimal dosing.
Patients should be trained how to use Aerivio Spiromax and advised to inhale forcefully to ensure optimal dosing.

Each metered dose of Aerivio Spiromax contains 50 microgram salmeterol and 500 microgram fluticasone propionate, the same as Seretide 500 Accuhaler. Each delivered dose provides 45 microgram salmeterol and 465 microgram fluticasone propionate.

Aerivio Spiromax is indicated in the regular treatment of severe asthma where use of a combination product (inhaled corticosteroid and long-acting β2 agonist) is appropriate, in patients who are either:

  • not adequately controlled on a lower-strength corticosteroid combination product, or
  • already controlled on a high-dose inhaled corticosteroid and a long-acting β2 agonist.

The product should not be prescribed as the first salmeterol/fluticasone combination inhaler in patients naive to such therapy.

In COPD, Aerivio Spiromax can be prescribed for adults with a pre-bronchodilator FEV1 less than 60% of the predicted normal and a history of exacerbations, who remain significantly symptomatic despite regular bronchodilator therapy.

The recommended dose in both asthma and COPD is one inhalation twice daily.

Dry powder inhaler

The Spiromax device, which is also available as DuoResp Spiromax (formoterol/budesonide, indicated in asthma and COPD), is a breath-actuated dry powder inhaler that has a design similar to that of pressurised metered-dose inhalers.

There are three steps to using the Spiromax inhaler: open, breathe and close. No priming is required. Dose confirmation is provided by a 'click' sound, lactose taste and a dose indicator.

When prescribing Aerivio Spiromax, healthcare professionals must ensure patients are trained in the use of the device including instruction on the need to inhale forcefully. Patients should be advised to not shake the inhaler before use or block the air vent when preparing the ‘breathe’ step.

Want news like this straight to your inbox?
Sign up for our bulletins

Read these next

New salmeterol/fluticasone MDI extends choice in asthma prescribing

New salmeterol/fluticasone MDI extends choice in asthma prescribing

Aloflute (salmeterol/fluticasone) metered dose inhaler...

Asthma and COPD Preparations and Compatible Devices

Asthma and COPD Preparations and Compatible Devices

Available presentations of bronchodilators and anti-inflammatories.

New salmeterol/fluticasone dry powder inhaler for COPD

New salmeterol/fluticasone dry powder inhaler for COPD

AirFluSal Forspiro (salmeterol/fluticasone) can be...

DuoResp Spiromax: new formoterol/budesonide inhaler

DuoResp Spiromax: new formoterol/budesonide inhaler

DuoResp Spiromax (formoterol/budesonide) has been launched...


Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

MIMS Product Slides

Product overviews prepared by the MIMS team, in a handy slide format.

Click here

Slides are initiated, funded & reviewed by the companies specified.

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases